Figure 2
HMR mutations included pathogenic and likely pathogenic variants in ASXL1, EZH2, IDH1/2, SRSF2, TP53, and U2AF1Q157. Abbreviations: AP, accelerated phase; BP, blast phase; HMR, high molecular risk; MPN, myeloproliferative neoplasm; NGS, next-generation sequencing; SMF, secondary myelofibrosis.
Proportion of patients with additional non-MPN driver mutations

HMR mutations included pathogenic and likely pathogenic variants in ASXL1, EZH2, IDH1/2, SRSF2, TP53, and U2AF1Q157. Abbreviations: AP, accelerated phase; BP, blast phase; HMR, high molecular risk; MPN, myeloproliferative neoplasm; NGS, next-generation sequencing; SMF, secondary myelofibrosis.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal